CONNECT: an open-label, active-controlled dimethyl fumarate study in pediatric patients with relapsing-remitting multiple sclerosis

被引：0
作者：
Maghzi, A. -H. [1 ]
Levin., S. [1 ]
Alroughani, R. [2 ]
Deiva, K. [3 ,4 ]
Pozzili, C. [5 ]
Lyons, J. [1 ]
Mokliatchouk, O. [1 ]
Pultz, J. [1 ]
N'Dure, F. [1 ]
Liu, S. [1 ]
Badwan, R. [1 ]
Branco, F. [1 ]
Franchimont, N. [1 ]
Hanna, J. [1 ]
Scaramozza, M. [1 ]
Vermersch, P. [6 ]
机构：
[1] Biogen, Cambridge, MA USA
[2] Dasman Diabet Inst, Dasman, Kuwait
[3] Univ Hosp Paris Saclay, Bicetre Hosp, AP HP, Pediat Neurol Dept, Le Kremlin Bicetre, France
[4] French Reference Network Rare Inflammatory Brain, Le Kremlin Bicetre, France
[5] Neurol Ctr Latium, Rome, Italy
[6] Univ Lille, CHU Lille, FHU Precise, INSERM,UMR U 1172, Lille, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 2_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P095
引用
收藏
页码：194 / 195
页数：2
相关论文
共 50 条
  • [1] Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
    de Sa, Joao
    Ferreira, Joao
    Macedo, Ana M.
    REVISTA DE NEUROLOGIA, 2023, 76 : S1 - S6
  • [2] A prospective, open-label, phase II study of oral fumarate therapy for the treatment of relapsing-remitting multiple sclerosis
    Schimrigk, S
    Brune, N
    Hellwig, K
    Rieks, M
    Hoffmann, V
    Pöhlau, D
    Przuntek, H
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S258 - S259
  • [3] Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
    Doosti, Rozita
    Moghadasi, Abdorreza Naser
    Azimi, Amir Reza
    Saleh, Shahrokh Karbalai
    Etemadifar, Masoud
    Shaygannejad, Vahid
    Ashtari, Fereshteh
    Harirchian, Mohammad Hossein
    Siroos, Seyed Bahaadin
    Ayramloo, Hormoz
    Majdinasab, Nastaran
    Hojjati, Seyyed Mohammad Masood
    Asghari, Nabiollah
    Baghbanian, Seyed Mohammad
    Cheraghmakani, Hamed
    Abedini, Mahmoud
    Sedighi, Behnaz
    Abadi, Negar Mohseni Abbas
    Ghasemitabar, Maedeh
    Talebianpour, Sara
    Daylari, Tohid Babayi
    Dana, Vahid
    Noie, Neda Ghaleh
    Sahraian, Mohammad Ali
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2021, 12 (03) : 263 - 274
  • [4] Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
    Bomprezzi, Roberto
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 20 - 30
  • [5] Interim Results of an Open-Label Study to Assess the Effects of Delayed-release Dimethyl Fumarate on Lymphocyte Subsets and Immunoglobulins in Patients with Relapsing-remitting Multiple Sclerosis
    Von Hehn, Christian
    Mehta, Devangi
    Prada, Claudia
    Yang, Lili
    Liu, Shifang
    Ray, Soma
    Sheikh, Sarah
    NEUROLOGY, 2017, 88
  • [6] Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Burness, Celeste B.
    Deeks, Emma D.
    CNS DRUGS, 2014, 28 (04) : 373 - 387
  • [7] Dimethyl Fumarate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Celeste B. Burness
    Emma D. Deeks
    CNS Drugs, 2014, 28 : 373 - 387
  • [8] QualiCOP: an open-label, prospective, observational study of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Calabrese, P.
    Penner, I. -K.
    Carroll, C. A.
    Apfel, R.
    JOURNAL OF NEUROLOGY, 2014, 261 : S229 - S229
  • [9] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [10] QualiCOP: an open-label, prospective, observational study of glatiramer acetate in patients with relapsing-remitting multiple sclerosis
    Ziemssen, T.
    Calabrese, P.
    Penner, I. -K.
    Carroll, C. A.
    Apfel, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 340 - 340
12345